- Home
- CHRD vs GKOS Comparison
CHRD vs GKOS Comparison
Compare CHRD & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRD
- GKOS
- Stock Information
- Founded
- CHRD 2007
- GKOS 1998
- Country
- CHRD United States
- GKOS United States
- Employees
- CHRD N/A
- GKOS N/A
- Industry
- CHRD Oil & Gas Production
- GKOS Medical/Dental Instruments
- Sector
- CHRD Energy
- GKOS Health Care
- Exchange
- CHRD Nasdaq
- GKOS Nasdaq
- Market Cap
- CHRD 5.1B
- GKOS 5.4B
- IPO Year
- CHRD 2010
- GKOS 2015
- Fundamental
- Price
- CHRD $91.01
- GKOS $95.98
- Analyst Decision
- CHRD Strong Buy
- GKOS Strong Buy
- Analyst Count
- CHRD 12
- GKOS 13
- Target Price
- CHRD $137.08
- GKOS $122.08
- AVG Volume (30 Days)
- CHRD 763.3K
- GKOS 1.6M
- Earning Date
- CHRD 11-04-2025
- GKOS 10-29-2025
- Dividend Yield
- CHRD 5.65%
- GKOS N/A
- EPS Growth
- CHRD N/A
- GKOS N/A
- EPS
- CHRD 2.96
- GKOS N/A
- Revenue
- CHRD $4,850,258,000.00
- GKOS $469,820,000.00
- Revenue This Year
- CHRD N/A
- GKOS $30.89
- Revenue Next Year
- CHRD N/A
- GKOS $24.36
- P/E Ratio
- CHRD $31.15
- GKOS N/A
- Revenue Growth
- CHRD 9.04
- GKOS 30.38
- 52 Week Low
- CHRD $79.83
- GKOS $73.16
- 52 Week High
- CHRD $134.54
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- CHRD 48.08
- GKOS 65.37
- Support Level
- CHRD $84.25
- GKOS $87.32
- Resistance Level
- CHRD $93.44
- GKOS $97.22
- Average True Range (ATR)
- CHRD 2.81
- GKOS 4.26
- MACD
- CHRD 0.70
- GKOS 1.09
- Stochastic Oscillator
- CHRD 69.71
- GKOS 93.59
About CHRD Chord Energy Corporation
Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.